Celsion Corporation (NASDAQ:CLSN) Stock Is Down 6% In a Week: Here is Why
Celsion Corporation (NASDAQ:CLSN) down 6% in a week. The company has announced that EVP and Chief Scientific Officer Khursheed Anwer will present Celsion’s GEN-1 interleukin 12 monotherapy during the Cytokine-Based Cancer Immunotherapies Summit taking place from November 30 to December 2, 2021, in Boston. Trading Data On Monday, CLSN stock went up 0.26% at $0.89 with more than 920K shares, compared to its average volume of 956K shares. The stock…